Understanding the regulation of Group B Streptococcal virulence factors

Future Microbiology

Volumn 4, Issue 2, 2009, Pages 201-221

  Rajagopal, Lakshmi ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

Bacteria; Gene expression; Gram positive; One component system; Pathogenesis; Serine threonine kinase; Signaling; Streptococcus agalactiae; Transcription; Two component system

Indexed keywords

ALPHAC PROTEIN; ANTIBIOTIC AGENT; BACTERIAL POLYSACCHARIDE; BACTERIAL PROTEIN; BETA HEMOLYSIN; COMPLEMENT COMPONENT C5A PEPTIDASE; CYCLIC AMP; CYTOLYSIN; FIBRINOGEN BINDING PROTEIN; HEMOLYSIN; HYALURONATE LYASE; LAMININ BINDING PROTEIN; METHIONINE TRANSPORT REGULATOR; PENICILLIN BINDING PROTEIN; POLYPEPTIDE ANTIBIOTIC AGENT; PORE FORMING CYTOTOXIC PROTEIN; SERINE PROTEINASE; SERINE RICH REPEAT PROTEIN; SIALIC ACID RICH CAPSULAR POLYSACCHARIDE; SUPEROXIDE DISMUTASE; UNCLASSIFIED DRUG; VIRULENCE FACTOR;

ADAPTIVE IMMUNITY; ANTIBIOTIC RESISTANCE; BACTERIAL COLONIZATION; BACTERIAL GROWTH; BACTERIAL METABOLISM; BACTERIAL SURVIVAL; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; BACTERIUM ADHERENCE; BACTERIUM PILUS; DRUG TARGETING; GROUP B STREPTOCOCCAL INFECTION; HUMAN; INNATE IMMUNITY; NONHUMAN; OXYGEN CONSUMPTION; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; STREPTOCOCCUS AGALACTIAE; SURFACE CHARGE; TRANSCRIPTION REGULATION; BIOSYNTHESIS; GENE EXPRESSION REGULATION; MICROBIOLOGY; PHYSIOLOGY; STREPTOCOCCUS INFECTION;

BACTERIA (MICROORGANISMS); POSIBACTERIA; STREPTOCOCCUS AGALACTIAE; STREPTOCOCCUS SP. 'GROUP B';

GENE EXPRESSION REGULATION, BACTERIAL; HUMANS; SIGNAL TRANSDUCTION; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS AGALACTIAE; VIRULENCE FACTORS;

EID: 63849257530     PISSN: 17460913     EISSN: None     Source Type: Journal    
DOI: 10.2217/17460913.4.2.201     Document Type: Review

References (182)

1. Berner R: Significance, management and prevention of Streptococcus agalactiae infection during the perinatal period. Expert Rev. Anti. Infect. Ther. 2, 427-437 (2004).
2. van der Poll T, Opal SM: Host-pathogen interactions in sepsis. Lancet Infect. Dis. 8, 3-43 (2008).
3. Campbell JR, Hillier SL, Krohn MA, Ferrieri P, Zaleznik DF, Baker CJ: Group B Streptococcal colonization and serotype-specific immunity in pregnant women at delivery. Obstet. Gynecol. 96, 498-503 (2000).
4. Mullaney DM: Group B Streptococcal infections in newborns. J. Obstet. Gynecol. Neonatal Nurs. 30, 649-658 (2001).
5. Cowgill K, Taylor TH Jr, Schuchat A, Schrag S: Report from the CDC. Awareness of perinatal Group B Streptococcal infection among women of childbearing age in the United States, 1999 and 2002. J. Womens Health (Larchmt) 12, 527-532 (2003).
6. Lin FY, Weisman LE, Troendle J, Adams K: Prematurity is the major risk factor for late-onset Group B Streptococcus disease. J. Infect. Dis. 188, 267-271 (2003).
7. Schrag SJ, Zywicki S, Farley MM et al.: Group B Streptococcal disease in the era of intrapartum antibiotic prophylaxis. N. Engl. J. Med. 342, 15-20 (2000).
8. Boyer KM, Vogel LC, Gotoff SP, Gadzala CA, Stringer J, Maxted WR: Nosocomial transmission of bacteriophage type 7/11/12 Group B Streptococci in a special care nursery. AMA Am. J. Dis. Child. 134, 964-966 (1980).
9. Tumbaga PF, Philip AGS: Perinatal Group B Streptococcal infections: past, present and future. NeoReviews 4, 65-72 (2003).
10. Pettersson K: Perinatal infection with Group B Streptococci. Semin. Fetal Neonatal Med. 12, 193-197 (2007).
11. Dermer P, Lee C, Eggert J, Few B: A history of neonatal Group B Streptococcus with its related morbidity and mortality rates in the United States. J. Pediatr. Nurs. 19, 357-363 (2004).
12. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn: Guidelines for prevention of Group B Streptococcal (GBS) infection by chemoprophylaxis. Pediatrics 90, 775-778 (1992).
13. American Academy of Pediatrics Committee on Infectious Diseases and Committee on Fetus and Newborn. Revised guidelines for prevention of early-onset Group B Streptococcal (GBS) infection. Pediatrics 99, 489-496 (1997).
14. Gibbs RS, Schrag S, Schuchat A: Perinatal infections due to Group B Streptococci. Obstet. Gynecol. 104, 1062-1076 (2004).
15. Lukacs SL, Schoendorf KC, Schuchat A: Trends in sepsis-related neonatal mortality in the United States, 1985-1998. Pediatr. Infect. Dis. J. 23, 599-603 (2004).
16. Edwards MS, Baker CJ: Group B Streptococcal infections in elderly adults. Clin. Infect. Dis. 41, 839-847 (2005).
17. Farley MM: Group B Streptococcal disease in nonpregnant adults. Clin. Infect. Dis. 33, 556-561 (2001).
18. Andrews JI, Diekema DJ, Hunter SK et al.: Group B Streptococci causing neonatal bloodstream infection: antimicrobial susceptibility and serotyping results from SENTRY centers in the western hemisphere. Am. J. Obstet. Gynecol. 183, 859-862 (2000).
19. Bland ML, Vermillion ST, Soper DE, Austin M: Antibiotic resistance patterns of Group B Streptococci in late third-trimester rectovaginal cultures. Am. J. Obstet. Gynecol. 184, 1125-1126 (2001).
20. Simoes JA, Aroutcheva AA, Heimler I, Faro S: Antibiotic resistance patterns of Group B Streptococcal clinical isolates. Infect. Dis. Obstet. Gynecol. 12, 1-8 (2004).
21. Heelan JS, Hasenbein ME, McAdam AJ: Resistance of Group B Streptococcus to selected antibiotics, including erythromycin and clindamycin. J. Clin. Microbiol. 42, 1263-1264 (2004).
22. Dahesh S, Hensler ME, van Sorge NM et al.: Point mutation in the Group B Streptococcal pbp2x gene conferring decreased susceptibility to β-lactam antibiotics. Antimicrob. Agents Chemother. 52, 2915-2918 (2008).
23. Kimura K, Suzuki S, J Wachino et al.: First molecular characterization of Group B Streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52, 2890-2897 (2008).
24. Nagano N, Nagano Y, Kimura K, Tamai K, Yanagisawa H, Arakawa Y: Genetic heterogeneity in pbp genes among clinically isolated Group B Streptococci with reduced penicillin susceptibility. Antimicrob. Agents Chemother. 52(12), 4258-4267 (2008).
25. Cieslewicz MJ, Chaffin D, Giusman G et al.: Structural and genetic diversity of Group B Streptococcus capsular polysaccharides. Infect. Immun. 73, 3096-3103 (2005).
26. Slotved HC, Kong F, Lambertsen L, Sauer S, Gilbert GL: Serotype IX, a proposed new Streptococcus agalactiae serotype. J. Clin. Microbiol. 45, 2929-2936 (2007).
27. Tettelin H, Masignani V, Cieslewicz MJ et al.: Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the microbial 'pan-genome'. Proc. Natl Acad. Sci. USA 102, 13950-13955 (2005).
28. Maisey HC, Doran KS, Nizet V: Recent advances in understanding the molecular basis of Group B Streptococcus virulence. Expert Rev. Mol. Med. 10, e27 (2008).
29. Miller SI, Mekalanos JJ: Constitutive expression of the phoP regulon attenuates Salmonella virulence and survival within macrophages. J. Bacteriol. 172, 2485-2490 (1990).
30. Mouslim C, Delgado M, Groisman EA: Activation of the RcsC/YojN/RcsB phosphorelay system attenuates Salmonella virulence. Mol. Microbiol. 54, 386-395 (2004).
31. Stephenson K, Hoch JA: Virulence- and antibiotic resistance-associated two-component signal transduction systems of Gram-positive pathogenic bacteria as targets for antimicrobial therapy. Pharmacol. Ther. 93, 293-305 (2002).
32. Johnson CD, Liu LX: Novel antimicrobial targets from combined pathogen and host genetics. Proc. Natl Acad. Sci. USA 97, 958-959 (2000).
33. Cohen P: Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
34. Hoch J, Silhavy TJ: Two-Component Signal Transduction. ASM Press, VA, USA (1995).
35. Glaser P, Rusniok C, Buchrieser C et al.: Genome sequence of Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol. Microbiol. 45, 1499-1513 (2002).
36. Tettelin H, Masignani V, Cieslewicz MJ et al.: Complete genome sequence and comparative genomic analysis of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc. Natl Acad. Sci. USA 99, 12391-12396 (2002).
37. Lamy MC, Zouine M, Fert J et al.: CovS/CovR of Group B Streptococcus: a two-component global regulatory system involved in virulence. Mol. Microbiol. 54, 1250-1268 (2004).
38. Jiang SM, Cieslewicz MJ, Kasper DL, Wessels MR: Regulation of virulence by a two-component system in Group B Streptococcus. J. Bacteriol. 187, 1105-1113 (2005).
39. Jiang SM, Ishmael N, Hotopp JD et al.: Variation in the Group B Streptococcus CsrRS regulon and effects on pathogenicity. J. Bacteriol. 190, 1956-1965 (2008).
40. Poyart C, Lamy MC, Boumaila C, Fiedler F, Trieu-Cuot P: Regulation of [s D s]-alanyl-lipotechoic acid biosynthesis in Streptococcus agalactiae involves a novel two-component regulatory system. J. Bacteriol. 183, 6324-6334 (2001).
41. Poyart C, Pellegrini E, Marceau M et al.: Attenuated virulence of Streptococcus agalactiae deficient in [s D s]-alanyl-lipoteichoic acid is due to an increased susceptibility to defensins and phagocytic cells. Mol. Microbiol. 49, 1615-1625 (2003).
42. Spellerberg B, Rozdzinski E, Martin S, Weber-Heynemann J, Lutticken R: rgf encodes a novel two-component signal transduction system of Streptococcus agalactiae. Infect. Immun. 70, 2434-2440 (2002).
43. Quach D, van Sorge NM, Kristian SA, Bryan JD, Shelver DW, Doran KS: The CiaR response regulator in Group B Streptococcus promotes intracellular survival and resistance to innate immune defenses. J. Bacteriol. (2008).
44. Ulrich LE, Koonin EV, Zhulin IB: One-component systems dominate signal transduction in prokaryotes. Trends Microbiol. 13, 52-56 (2005).
45. Kreikemeyer B, McIver KS, Podbielski A: Virulence factor regulation and regulatory networks in Streptococcus pyogenes and their impact on pathogen-host interactions. Trends Microbiol. 11, 224-232 (2003).
46. Shelver D, Rajagopal L, Harris TO, Rubens CE: MtaR, a regulator of methionine transport, is critical for survival of Group B Streptococcus in vivo. J. Bacteriol. 185, 6592-6599 (2003).
47. Bryan JD, Liles R, Cvek U, Trutschl M, Shelver D: Global transcriptional profiling reveals Streptococcus agalactiae genes controlled by the MtaR transcription factor. BMC Genomics 9, 607 (2008).
48. Gutekunst H, Eikmanns BJ, Reinscheid DJ: Analysis of RogB-controlled virulence mechanisms and gene repression in Streptococcus agalactiae. Infect. Immun. 71, 5056-5064 (2003).
49. Samen UM, Eikmanns BJ, Reinscheid DJ: The transcriptional regulator RovS controls the attachment of Streptococcus agalactiae to human epithelial cells and the expression of virulence genes. Infect. Immun. 74, 5625-5635 (2006).
50. Rajagopal L, Ciancy A, Rubens CE: A eukaryotic type serine/threonine kinase and phosphatase in Streptococcus agalactiae reversibly phosphorylate an inorganic pyrophosphatase and affect growth, cell segregation, and virulence. J. Biol. Chem. 278, 14429-14441 (2003).
51. Rajagopal L, Vo A, Silvestroni A, Rubens CE: Regulation of purine biosynthesis by a eukaryotic-type kinase in Streptococcus agalactiae. Mol. Microbiol. 56, 1329-1346 (2005).
52. Rajagopal L, Vo A, Silvestroni A, Rubens CE: Regulation of cytotoxin expression by converging eukaryotic-type and two-component signaling mechanisms in Streptococcus agalactiae. Mol. Microbiol. 62, 941-957 (2006).
53. Lin WJ, Walthers D, Connelly JE et al.: Threonine phosphorylation prevents promoter DNA binding of the Group B Streptococcus response regulator CovR. Mol. Microbiol. (2009).
54. Churchward G: The two faces of Janus: virulence gene regulation by CovR/ S in Group A Streptococci. Mol. Microbiol. 64, 34-41 (2007).
55. Hondorp ER, McIver KS: The Mga virulence regulon: infection where the grass is greener. Mol. Microbiol. 66, 1056-1065 (2007).
56. Novick RP: Autoinduction and signal transduction in the regulation of staphylococcal virulence. Mol. Microbiol. 48, 1429-1449 (2003).
57. Novick RP: Medicine. Combating impervious bugs. Science 319, 910-911 (2008).
58. Aroian R, van der Goot FG: Pore-forming toxins and cellular non-immune defenses (CNIDs). Curr. Opin. Microbiol. 10, 57-61 (2007).
59. Gonzalez, MR, Bischofberger M, Pernot L, van der Goot FG, Freche B: Bacterial pore-forming toxins: the (w)hole story? Cell. Mol. Life Sci. 65, 493-507 (2008).
60. Nizet V, Gibson RL, Chi EY, Framson PE, Hulse M, Rubens CE: Group B Streptococcal β-hemolysin expression is associated with injury of lung epithelial cells. Infect. Immun. 64, 3818-3826 (1996).
61. Nizet V, Gibson RL, Rubens CE: The role of Group B Streptococci β-hemolysin expression in newborn lung injury. Adv. Exp. Med. Biol. 418,627-630 (1997).
62. Gibson RL, Nizet V, Rubens CE: Group B Streptococcal β-hemolysin promotes injury of lung microvascular endothelial cells. Pediatr. Res. 45, 626-634 (1999).
63. Doran KS, Chang JC, Benoit VM, Eckmann L, Nizet V: Group B Streptococcal β-hemolysin/cytolysin promotes invasion of human lung epithelial cells and the release of interleukin-8. J. Infect. Dis. 185, 196-203 (2002).
64. Doran KS, Liu GY, Nizet V: Group B Streptococcal β-hemolysin /cytolysin activates neutrophil signaling pathways in brain endothelium and contributes to development of meningitis. J. Clin. Invest. 112, 736-744 (2003).
65. Hensler ME, Miyamoto S, Nizet V: Group B Streptococcal β-hemolysin/ cytolysin directly impairs cardiomyocyte viability and function. PLoS ONE3, e2446 (2008).
66. Ring A, Braun JS, Pohl J, Nizet V, Stremmel W, Shenep JL: Group B Streptococcal β-hemolysin induces mortality and liver injury in experimental sepsis. J. Infect. Dis. 185, 1745-1753 (2002).
67. Ring A, Braun JS, Nizet V, Stremmel W, Shenep JL: Group B Streptococcal β-hemolysin induces nitric oxide production in murine macrophages. J. Infect. Dis. 182, 150-157 (2000).
68. Hensler ME, Liu GY, Sobczak S, Benirschke K, Nizet V, Heldt GP: Virulence role of Group B Streptococcus β-hemolysin/cytolysin in a neonatal rabbit model of early-onset pulmonary infection. J. Infect. Dis. 191, 1287-1291 (2005).
69. Puliti M, Nizet V, von Hunolstein C et al.: Severity of Group B Streptococcal arthritis is correlated with β-hemolysin expression. J. Infect. Dis. 182, 824-832 (2000).
70. Pritzlaff CA, Chang JC, Kuo SP, Tamura GS, Rubens CE, Nizet V: Genetic basis for the β-haemolytic/cytolytic activity of Group B Streptococcus. Mol. Microbiol. 39, 236-247 (2001).
71. Spellerberg B, Pohl B, Haase G, Martin S, Weber-Heynemann J, Lutticken R: Identification of genetic determinants for the hemolytic activity of Streptococcus agalactiae by ISS1 transposition. J. Bacteriol. 181, 3212-3219 (1999).
72. Forquin ME Tazi A, Rosa-Fraile M, Poyart C, Trieu-Cuot P, Dramsi S: The putative glycosyltransferase-encoding gene cylJ and the Group B Streptococcus (GBS)-specific gene cylK modulate hemolysin production and virulence of GBS. Infect. Immun. 75, 2063-2066 (2007).
73. Gottschalk B, Broker G, Kuhn M, Aymanns S, Gleich-Theurer U, Spellerberg B: Transport of multidrug resistance substrates by the Streptococcus agalactiae hemolysin transporter. J. Bacteriol. 188, 5984-5992 (2006).
74. Nizet V: Streptococcal β-hemolysins: genetics and role in disease pathogenesis. Trends Microbiol. 10, 575-580 (2002).
75. Spellerberg B, Martin S, Brandt C, Lutticken R: The cyl genes of Streptococcus agalactiae are involved in the production of pigment. FEMS Microbiol. Lett. 188, 125-128 (2000).
76. Tapsall JW: Pigment production by Lancefield-Group-B Streptococci (Streptococcus agalactiae). J. Med. Microbiol. 21, 75-81 (1986).
77. Liu GY, Doran KS, Lawrence T et al.: Sword and shield: linked Group B Streptococcal β-hemolysin/cytolysin and carotenoid pigment function to subvert host phagocyte defense. Proc. Nad Acad. Sci. USA 101, 14491-14496 (2004).
78. Fang FC: Antimicrobial reactive oxygen and nitrogen species: concepts and controversies. Nat. Rev. Microbiol. 2, 820-832 (2004).
79. Rosa-Fraile M, Rodriguez-Granger J, Haidour-Benamin A, Cuerva JM, Sampedro A: Granadaene: proposed structure of the Group B Streptococcus polyenic pigment. Appl. Environ. Microbiol. 72, 6367-6370 (2006).
80. Krinsky NI, Yeum KJ: Carotenoid-radical interactions. Biochem. Biophys. Res. Commun. 305, 754-760 (2003).
81. Mathews MM, Sistrom WR: Function of carotenoid pigments in non-photosynthetic bacteria. Nature 184(Suppl. 24), 1892-1893 (1959).
82. Rajagopal L, Sundari CS, Balasubramanian D, Sonti RV: The bacterial pigment xanthomonadin offers protection against photodamage. FEBS Lett. 415, 125-128 (1997).
83. Ulijasz AT, Falk SP, Weisblum B: Phosphorylation of the RitR DNA-binding domain by a Ser-Thr phosphokinase: implications for global gene regulation in the streptococci. Mol. Microbiol. 71(2), 382-390. (2008).
84. Lang S, Palmer M: Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin. J. Biol. Chem. 278, 38167-38173 (2003).
85. Podbielski A, Blankenstein O, Lutticken R: Molecular characterization of the cfb gene encoding Group B Streptococcal CAMP-factor. Med. Microbiol. Immunol. (Berl.) 183, 239-256 (1994).
86. Jurgens D, Sterzik B, Fehrenbach FJ: Unspecific binding of Group B Streptococcal cocytolysin (CAMP factor) to immunoglobulins and its possible role in pathogenicity. J. Exp. Med. 165, 720-732 (1987).
87. Skalka B, Smola J: Lethal effect of CAMP-factor and UBERIS-factor - a new finding about diffusible exosubstances of Streptococcus agalactiae and Streptococcus uberis. Zentralbl. Bakteriol. A 249, 190-194 (1981).
88. Lang S, Palmer M: Characterization of Streptococcus agalactiae CAMP factor as a pore-forming toxin. J. Biol. Chem. 278, 38167-38173 (2003).
89. Lang S, Xue J, Guo Z, Palmer M: Streptococcus agalactiae CAMP factor binds to GPI-anchored proteins. Med. Microbiol. Immunol. 196, 1-10 (2007).
90. Hensler ME, Quach D, Hsieh CJ, Doran KS, Nizet V: CAMP factor is not essential for systemic virulence of Group B Streptococcus. Microb. Pathog. 44, 84-88 (2008).
91. Jiang SM, Ishmael N, Hotopp JD et al.: Variation in the Group B Streptococcus CsrRS regulon and effects on pathogenicity. J. Bacteriol. 190, 1956-1965 (2008).
92. Marques MB, Kasper DL, Pangburn MK, Wessels MR: Prevention of C3 deposition by capsular polysaccharide is a virulence mechanism of type III Group B Streptococci. Infect. Immun. 60, 3986-3993 (1992).
93. Campbell JR, Baker CJ, Edwards MS: Deposition and degradation of C3 on type III Group B Streptococci. Infect. Immun. 59, 1978-1983 (1991).
94. Baker CJ, Kasper DL: Correlation of maternal antibody deficiency with susceptibility to neonatal Group B Streptococcal infection. N. Engl. J. Med. 294, 753-756 (1976).
95. Rubens CE, Wessels MR, Heggen LM, Kasper DL: Transposon mutagenesis of type III Group B Streptococcus: correlation of capsule expression with virulence. Proc. Natl Acad. Sci. USA 84, 7208-7212 (1987).
96. Wessels MR, Rubens CE, Benedi VJ, Kasper DL: Definition of a bacterial virulence factor: sialylation of the Group B Streptococcal capsule. Proc. Natl Acad. Sci. USA 86, 8983-8987 (1989).
97. Martin TR, Ruzinski JT, Rubens CE, Chi EY, Wilson CB: The effect of type-specific polysaccharide capsule on the clearance of Group B Streptococci from the lungs of infant and adult rats. J. Infect. Dis. 165, 306-314 (1992).
98. Wessels MR, Haft RF, Heggen LM, Rubens CE: Identification of a genetic locus essential for capsule sialylation in type III Group B Streptococci. Infect. Immun. 60, 392-400 (1992).
99. Marques MB, Kasper DL, Shroff A, Michon F, Jennings HJ, Wessels MR: Functional activity of antibodies to the group B polysaccharide of Group B Streptococci elicited by a polysaccharide-protein conjugate vaccine. Infect. Immun. 62, 1593-1599 (1994).
100. Paoletti LC, Kasper DL: Glycoconjugate vaccines to prevent Group B Streptococcal infections. Expert Opin. Biol. Ther. 3, 975-984 (2003).
101. Paoletti LC, Kasper DL, Michon F et al.: An oligosaccharide-tetanus toxoid conjugate vaccine against type III Group B Streptococcus. J. Biol. Chem. 265, 18278-18283 (1990).
102. Paoletti LC, Kasper DL: Conjugate vaccines against Group B Streptococcus types IV and VII. J. Infect. Dis. 186, 123-126 (2002).
103. Johri AK, Paoletti LC, Glaser P et al.: Group B Streptococcus: global incidence and vaccine development. Nat. Rev. Microbiol. 4, 932-942 (2006).
104. Edwards MS: Group B Streptococcal conjugate vaccine: a timely concept for which the time has come. Hum. Vaccin. 4, 444-448 (2008).
105. Paoletti LC, Guttormsen HK, Christian MS, Hoberman AM, McInnes P: Neither antibody to a Group B Streptococcal conjugate vaccine nor the vaccine itself is teratogenic in rabbits. Hum. Vaccin. 4, 435-443 (2008).
106. Lewis AL, Nizet V, Varki A: Discovery and characterization of sialic acid O-acetylation in Group B Streptococcus. Proc. Natl Acad. Sci. USA 101, 11123-11128 (2004).
107. Berry DS, Lynn F, Lee CH, Frasch CE, Bash MC: Effect of O-acetylation of Neisseria meningitidis serogroup A capsular polysaccharide on development of functional immune responses. Infect. Immun. 70, 3707-3713 (2002).
108. McNeely TB, Staub JM, Rusk CM, Blum MJ, Donnelly JJ: Antibody responses to capsular polysaccharide backbone and O-acetate side groups of Streptococcus pneumoniae type 9V in humans and rhesus macaques. Infect. Immun. 66, 3705-3710 (1998).
109. Lewis AL, Cao H, Patel SK et al.: NeuA sialic acid O-acetylesterase activity modulates O-acetylation of capsular polysaccharide in Group B Streptococcus. J. Biol. Chem. 282, 27562-27571 (2007).
110. Hulse ML, Smith S, Chi EY, Pham A, Rubens CE: Effect of type III Group B Streptococcal capsular polysaccharide on invasion of respiratory epithelial cells. Infect. Immun. 61, 4835-4841 (1993).
111. Tamura GS, Kuypers JM, Smith S, Raff H, Rubens CE: Adherence of Group B Streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface components. Infect. Immun. 62, 2450-2458 (1994).
112. Nizet V, Kim KS, Stins M et al.: Invasion of brain microvascular endothelial cells by Group B Streptococci. Infect. Immun. 65, 5074-5081 (1997).
113. Paoletti LC, Ross RA, Johnson KD: Cell growth rate regulates expression of Group B Streptococcus type III capsular polysaccharide. Infect. Immun. 64, 1220-1226 (1996).
114. Ross RA, Madoff LC, Paoletti LC: Regulation of cell component production by growth rate in the Group B Streptococcus. J. Bacteriol. 181, 5389-5394 (1999).
115. Johri AK, Patwardhan V, Paoletti LC: Growth rate and oxygen regulate the interactions of Group B Streptococcus with polarized respiratory epithelial cells. Can. J. Microbiol. 51, 283-286 (2005).
116. Malin G, Paoletti LC: Use of a dynamic in vitro attachment and invasion system (DIVAS) to determine influence of growth rate on invasion of respiratory epithelial cells by Group B Streptococcus. Proc. Natl Acad. Sci. USA 98, 13335-13340 (2001).
117. Poyart C, Pellegrini E, Gaillot O, Boumaila C, Baptista M, Trieu-Cuot P: Contribution of Mn-cofactored superoxide dismutase (SodA) to the virulence of Streptococcus agalactiae. Infect. Immun. 69, 5098-5106 (2001).
118. Takahashi S, Nagano Y, Nagano N, Hayashi O, Taguchi F, Okuwaki Y: Role of C5a-ase in Group B Streptococcal resistance to opsonophagocytic killing. Infect. Immun. 63, 4764-4769 (1995).
119. Bohnsack JF, Widjaja K, Ghazizadeh S et al.: A role for C5 and C5a-ase in the acute neutrophil response to Group B Streptococcal infections. J. Infect. Dis. 175, 847-855 (1997).
120. Cheng Q, Stafslien D, Purushothaman SS, Cleary P: The Group B Streptococcal C5a peptidase is both a specific protease and an invasin. Infect. Immun. 70, 2408-2413 (2002).
121. Beckmann C, Waggoner JD, Harris TO, Tamura GS, Rubens CE: Identification of novel adhesins from Group B Streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding. Infect. Immun. 70, 2869-2876 (2002).
122. Tamura GS, Hull JR, Oberg MD, Castner DG: High-affinity interaction between fibronectin and the Group B Streptococcal C5a peptidase is unaffected by a naturally occurring four-amino-acid deletion that eliminates peptidase activity. Infect. Immun. 74, 5739-5746 (2006).
123. Hull JR, Tamura GS, Castner DG: Interactions of the streptococcal C5a peptidase with human fibronectin. Acta Biomater. 4, 504-513 (2008).
124. Cheng Q, Debol S, Lam H et al.: Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate vaccines enhances clearance of Group B Streptococci from lungs of infected mice. Infect. Immun. 70, 6409-6415 (2002).
125. Santillan DA, Andracki ME, Hunter SK: Protective immunization in mice against Group B Streptococci using encapsulated C5a peptidase. Am. J. Obstet. Gynecol. 198, 114 e1-e6 (2008).
126. Harris TO, Shelver DW, Bohnsack JF, Rubens CE: A novel streptococcal surface protease promotes virulence, resistance to opsonophagocytosis, and cleavage of human fibrinogen. J. Clin. Invest. 111, 61-70 (2003).
127. Bryan JD, Shelver DW: Streptococcus agalactiae CspA is a serine protease that inactivates chemokines. J. Bacteriol. (2008).
128. Dramsi S, Caliot E, Bonne I et al.: Assembly and role of pili in Group B Streptococci. Mol. Microbiol. 60, 1401-1413 (2006).
129. Nobbs AH, Rosini R, Rinaudo CD, Maione D, Grandi G, Telford JL: Sortase A utilizes an ancillary protein anchor for efficient cell wall anchoring of pili in Streptococcus agalactiae. Infect. Immun. 76, 3550-3560 (2008).
130. Lalioui L, Pellegrini E, Dramsi S et al.: The SrtA sortase of Streptococcus agalactiae is required for cell wall anchoring of proteins containing the LPXTG motif, for adhesion to epithelial cells, and for colonization of the mouse intestine. Infect. Immun. 73, 3342-3350 (2005).
131. Hancock RE, Diamond G: The role of cationic antimicrobial peptides in innate host defences. Trends Microbiol. 8, 402-410 (2000).
132. Nizet V, Gallo RL: Surviving innate immunity. Trends Microbiol. 10, 358-359 (2002).
133. Peschel A: How do bacteria resist human antimicrobial peptides? Trends Microbiol. 10, 179-186 (2002).
134. Gryllos I, Tran-Winkler HJ, Cheng MF et al.: Induction of Group A Streptococcus virulence by a human antimicrobial peptide. Proc. Natl Acad. Sci. USA 105, 16755-16760 (2008).
135. Froehlich BJ, Bates C, Scott JR: Streptococcus pyogenes CovR/S mediates growth in iron starvation and in the presence of the human cationic antimicrobial peptide LL-37. J. Bacteriol. 191(2), 673-677 (2009).
136. Spratt BG, Cromie KD: Penicillin-binding proteins of gram-negative bacteria. Rev. Infect. Dis. 10, 699-711 (1988).
137. Georgopapadakou NH, Liu FY: Penicillin-binding proteins in bacteria. Antimicrob. Agents Chemother. 18, 148-157 (1980).
138. Zapun A, Contreras-Martel C, Vernet T: Penicillin-binding proteins and β-lactam resistance. FEMS Microbiol. Rev. 32, 361-385 (2008).
139. Jones AL, Needham RH, Clancy A, Knoll KM, Rubens CE: Penicillin-binding proteins in Streptococcus agalactiae: a novel mechanism for evasion of immune clearance. Mol. Microbiol. 47, 247-256 (2003).
140. Jones AL, Knoll KM, Rubens CE: Identification of Streptococcus agalactiae virulence genes in the neonatal rat sepsis model using signature-tagged mutagenesis. Mol. Microbiol. 37, 1444-1455 (2000).
141. Jones AL, Mertz RH, Carl DJ, Rubens CE: A streptococcal penicillin-binding protein is critical for resisting innate airway defenses in the neonatal lung. J. Immunol. 179, 3196-3202 (2007).
142. Hamilton A, Popham DL, Carl DJ, Lauth X, Nizet V, Jones AL: Penicillin-binding protein la promotes resistance of Group B Streptococcus to antimicrobial peptides. Infect. Immun. 74, 6179-6187 (2006).
143. Lauer P, Rinaudo CD, Soriani M et al.: Genome analysis reveals pili in Group B Streptococcus. Science 309, 105 (2005).
144. Pezzicoli A, Santi I, Lauer P et al.: Pilus backbone contributes to Group B Streptococcus paracdlular translocation through epithelial cells. J. Infect. Dis. 198, 890-898 (2008).
145. Maisey HC, Hensler M, Nizet V, Doran KS: Group B Streptococcal pilus proteins contribute to adherence to and invasion of brain microvascular endothelial cells. J. Bacteriol. 189, 1464-1467 (2007).
146. Maisey HC, Quach D, Hensler ME et al.: A Group B Streptococcal pilus protein promotes phagocyte resistance and systemic virulence. FASEB J. 22, 1715-1724 (2008).
147. Rosini R, Rinaudo CD, Soriani M et al.: Identification of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. Mol. Microbiol. 61, 126-141 (2006).
148. Buccato S, Malone D, Rinaudo CD et a. : Use of Lactococcus lactis expressing pili from Group B Streptococcus as a broad-coverage vaccine against streptococcal disease. J. Infect. Dis. 194, 331-340 (2006).
149. Telford JL, Barocchi MA, Margarit I, Rappuoli R, Grandi G: Pili in Gram-positive pathogens. Nat. Rev. Microbiol. 4, 509-519 (2006).
150. Maione D, Margarit I, Rinaudo CD et al.: Identification of a universal Group B Streptococcus vaccine by multiple genome screen. Science 309, 148-150 (2005).
151. Schubert A, Zakikhany K, Schreiner M et al.: A fibrinogen receptor from Group B Streptococcus interacts with fibrinogen by repetitive units with novel ligand binding sites. Mol. Microbiol. 46, 557-569 (2002).
152. Jacobsson K: A novel family of fibrinogen-binding proteins in Streptococcus agalactiae. Vet. Microbiol. 96, 103-113 (2003).
153. Gutekunst H, Eikmanns BJ, Reinscheid DJ: The novel fibrinogen-binding protein FbsB promotes Streptococcus agalactiae invasion into epithelial cells. Infect. Immun. 72, 3495-3504 (2004).
154. Spellerberg B, Rozdzinski E, Martin S et al.: Lmb, a protein with similarities to the LraI adhesin family, mediates attachment of Streptococcus agalactiae to human laminin. Infect. Immun. 67, 871-878 (1999).
155. Tenenbaum T, Spellerberg B, Adam R, Vogel M, Kim KS, Schroten H: Streptococcus agalactiae invasion of human brain microvascular endothelial cells is promoted by the laminin-binding protein Lmb. Microbes Infect. 9, 714-720 (2007).
156. Siboo IR, Chambers HF, Sullam PM: Role of SraP, a serine-rich surface protein of Staphylococcus aureus, in binding to human platelets. Infect. Immun. 73, 2273-2280 (2005).
157. Takamatsu D, Bensing BA, Cheng H et al.: Binding of the Streptococcus gordonii surface glycoproteins GspB and Hsa to specific carbohydrate structures on platelet membrane glycoprotein Ibα. Mol. Microbiol. 58, 380-392 (2005).
158. Seifert KN, Adderson EE, Whiting AA, Bohnsack JF, Crowley PJ, Brady LJ: A unique serine-rich repeat protein (Srr-2) and novel surface antigen (ε) associated with a virulent lineage of serotype III Streptococcus agalactiae. Microbiology 152, 1029-1040 (2006).
159. Samen U, Eikmanns BJ, Reinscheid DJ, Borges F: The surface protein Srr-1 of Streptococcus agalactiae binds human keratin 4 and promotes adherence to epithelial HEp-2 cells. Infect. Immun. 75, 5405-5414 (2007).
160. Santi I, Scarselli M, Mariani M et al.: BibA: a novel immunogenic bacterial adhesin contributing to Group B Streptococcus survival in human blood. Mol. Microbiol. 63, 754-767 (2007).
161. Mereghetti L, Sitkiewicz I, Green NM, Musser JM: Remodeling of the Streptococcus agalactiae transcriptome in response to growth temperature. PLoS ONE 3, e2785 (2008).
162. Michel JL, MadoffL C, Kling DE, Kasper DL, Ausubel FM: Cloned α and β C-protein antigens of Group B Streptococci elicit protective immunity. Infect. Immun. 59, 2023-2028 (1991).
163. Johnson DR, Ferrieri P: Group B Streptococcal Ibc protein antigen: distribution of two determinants in wild-type strains of common serotypes. J. Clin. Microbiol. 19, 506-510 (1984).
164. Baron MJ, Bolduc GR, Goldberg MB, Auperin TC, Madoff LC: αC protein of Group B Streptococcus binds host cell surface glycosaminoglycan and enters cells by an actin-dependent mechanism. J. Biol. Chem. 279, 24714-24723 (2004).
165. Baron MJ, Filman DJ, Prophete GA, Hogle JM, Madoff LC: Identification of a glycosaminoglycan binding region of the αC protein that mediates entry of Group B Streptococci into host cells. J. Biol. Chem. 282, 10526-10536 (2007).
166. Bolduc GR, Madoff LC: The Group B Streptococcal α C protein binds α1β 1-integrin through a novel KTD motif that promotes internalization of GBS within human epithelial cells. Microbiology 153, 4039-4049 (2007).
167. Doran KS, Engelson EJ, Khosravi A et al.: Blood-brain barrier invasion by Group B Streptococcus depends upon proper cell-surface anchoring of lipoteichoic acid. J. Clin. Invest. 115, 2499-2507 (2005).
168. Lin B, Hollingshead SK, Coligan JE, Egan ML, Baker JR, Pritchard DG: Cloning and expression of the gene for Group B Streptococcal hyaluronate lyase. J. Biol. Chem. 269, 30113-30116 (1994).
169. Gase K, Ozegowski J, Malke H: The Streptococcus agalactiae hylB gene encoding hyaluronate lyase: completion of the sequence and expression analysis. Biochimica Biophysica Acta 1398, 86-98 (1998).
170. Laurent TC, Fraser JR: Hyaluronan. FASEB J. 6, 2397-2404 (1992).
171. Lindahl U, Hook M: Glycosaminoglycans and their binding to biological macromolecules. Annu. Rev. Biochem. 47, 385-417 (1978).
172. Li S, Jedrzejas MJ: Hyaluronan binding and degradation by Streptococcus agalactiae hyaluronate lyase. J. Biol. Chem. 276, 41407-41416 (2001).
173. Pritchard DG, Lin B, Willingham TR, Baker JR: Characterization of the Group B Streptococcal hyaluronate lyase. Arch. Biochem. Biophys. 315, 431-437 (1994).
174. 2+ in the functional regulation of enzyme. J. Biol. Chem. 281, 28336-28344 (2006).
175. Milligan TW, Baker CJ, Straus DC, Mattingly SJ: Association of elevated levels of extracellular neuraminidase with clinical isolates of type III Group B Streptococci. Infect. Immun. 21, 738-746 (1978).
176. Juul SE, Kinsella MG, Truog WE, Gibson RL, Redding GJ: Lung hyaluronan decreases during Group B Streptococcal pneumonia in neonatal piglets. American Am. J. Respir. Crit. Care Med. 153, 1567-1570 (1996).
177. Johri AK, Margarit I, Broenstrup M et al.: Transcriptional and proteomic profiles of Group B Streptococcus type V reveal potential adherence proteins associated with high-level invasion. Infect. Immun. 75, 1473-1483 (2007).
178. Clancy A, Loar JW, Speziali CD, Oberg M, Heinrichs DE, Rubens CE: Evidence for siderophore-dependent iron acquisition in Group B Streptococcus. Mol. Microbiol. 59, 707-721 (2006).
179. Mereghetti L, Sitkiewicz I, Green NM, Musser JM: Extensive adaptive changes occur in the transcriptome of Streptococcus agalactiae
180. 2+ signalling defines the Group A Streptococcal CsrRS (CovRS) regulon. Mol. Microbiol. 65, 671-683 (2007)
181. Mascher T, Helmann JD, Unden G: Stimulus perception in bacterial signal-transducing histidine kinases. Microbiol. Mol. Biol. Rev. 70, 910-938 (2006).
182. Li M, Cha DJ, Lai Y, Villaruz AE, Sturdevant DE, Otto M: The antimicrobial peptide-sensing system aps of Staphylococcus aureus. Mol. Microbiol. 66, 1136-1147 (2007).